Document Type : Original Article


1 Faculty of Biology, Women's university of semnan (Farzanegan), Semnan, Iran

2 Department of Biotechnology, Faculty of Basic Science, Ale-Taha Institute of Higher Education, Tehran, Iran


PTEN is a tumor suppressor gene with important roles in apoptosis. This gene is located on chromosome 10q23 and is one of the most frequently inactivated genes in cancers. Severe underexpression of PTEN has been reported in several types of cancer, including endometrial, prostate, breast, and brain cancer. Also, this gene is epigenetically silenced through aberrant hypermethylation of CpG islands on its promoter. The present study investigated the promoter methylation and expression levels of PTEN in patients with Non-Small Cell Lung Carcinoma (NSCLC).
The study included 20 patients with NSCLC, whose bisulfite-treated DNA samples were investigated using the Methyl-Specific PCR (MSP) with primers specific for either methylated or non-methylated forms of PTEN. PTEN expression was also assessed using real-time PCR.
 20 samples from NSCLC patients, 70% (n=14) showed PTEN underexpression, while 85% (n=17) had PTEN promoter methylation. Also, 12 of 17 (70%) samples with PTEN promoter methylation had concomitant PTEN underexpression.
According to our results, there was a significant correlation between the PTEN promoter methylation and NSCLC. PTEN underexpression and promoter methylation were also significantly correlated.


1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Crystal AS, Shaw AT. New targets in advanced NSCLC:
EML4ALK. Clin Adv Hematol Oncol 2011; 9: 207-14.
3. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M.
Expression of selected gene for acquired drug resistance to EGFR-
TKI in lung adenocarcinoma. Lung Cancer 2011; 73: 361-5.
4. Li J, Yen C, Liaw D, etal. PTEN, a putative protein tyrosine
phosphatase gene mutated in human brain, breast, and prostate
cancer. Science 1997; 275: 1943-7.
5. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative
regulation of PKB/Akt-dependent cell survival by the tumor
suppressor PTEN. Cell 1998; 95: 29-39.
6. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and
genotype-phenotype analyses in Cowden disease and Bannayan-
Zonana syndrome, two hamartoma syndromes with germline
PTEN mutation. Hum Mol Genet 1998; 7: 507-15.
7. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in
glioblastoma multiforme. Cancer Res 1997; 57: 4183-6.
8. Kang YH, Lee HS, Kim WH. Promoter methylation and
silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82:
9. Marsit CJ, Zheng S, Aldape K, et al. PTEN expression in
non-small-cell lung cancer: evaluating its relation to tumor
characteristics, allelic loss, and epigenetic alteration. Hum Pathol
2005; 36: 768-76.
10. Uramoto H, Mitsudomi T. Which biomarker predicts benefit
from EGFR-TKI treatment for patients with lung cancer? Br J
Cancer 2007; 96: 857-63.
11. Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T,
Yasumoto K. Resistance to gefitinib. Int J Clin Oncol 2006; 11:
12. Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN
expression by blocking nuclear translocation of EGR1 in gefitinib-
resistant lung cancer cells harboring epidermal growth factor
receptor-activating mutations. Cancer Res 2010; 70: 8715-25.
13. Yoo SB, Lee HJ, Park JO, et al. Reliability of chromogenic
in situ hybridization for epidermal growth factor receptor gene
copy number detection in non-small-cell lung carcinomas: a
comparison with fluorescence in situ hybridization study. Lung
Cancer 2010; 67: 301-5.
14. Travis W, Brambilla E, Muller-Hermelink HK, Harris CC.
World Health Organization classification of tumours: pathology
and genetics of tumours of the lung, pleura, thymus and heart.
Lyon: IARC
15. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung
Cancer Staging Project: proposals for revision of the M descriptors
in the forthcoming (seventh) edition of the TNM classification of
lung cancer. J Thorac Oncol 2007; 2: 686-93.
16. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS, Lee YC.
Clonality and prognostic implications of p53 and epidermal
growth factor receptor somatic aberrations in multiple primary
lung cancers. Clin Cancer Res 2007; 13: 52-8.
17. Gallegos Ruiz MI, Floor K, Vos W, et al. Epidermal growth
factor receptor (EGFR) gene copy number detection in non-small
cell lung cancer: a comparison of fluorescence in situ hybridization
and chromogenic in situ hybridization. Histopathology 2007; 51:
18. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt
overexpression and loss of PTEN expression in non-small cell
lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-
19. Jiang Z, Wang X. Expression and significance of PTEN
and nm23H1 in the metastasis of non-small cell lung cancer..
Zhongguo Fei Ai Za Zhi 2008; 11: 793-7.
20. Lim WT, Zhang WH, Miller CR, et al. PTEN and
phosphorylated AKT expression and prognosis in early- and late-
stage non-small cell lung cancer. Oncol Rep 2007; 17: 853-7.
21. Zhang H, Shu H, Jiang W. Expression of PTEN, p53 and
P-glycoprotein in non-small cell lung cancer and their predictive
values. Zhongguo Fei Ai Za Zhi 2009; 12: 1213-6.
22. Liao DW, Wang L, Zhang XG, Liu MQ. Expression and
significance of PTEN/PI3K signal transduction-related proteins in
non-small cell lung cancer. Ai Zheng 2006; 25: 1238-42.